We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up
Read MoreHide Full Article
Aurinia Pharmaceuticals Inc. (AUPH - Free Report) announced that its pipeline candidate, voclosporin, met the primary endpoint in a pivotal phase III AURORA study evaluating it in patients with lupus nephritis ("LN"), an inflammation of the kidney caused by systemic lupus erythematosus. Data showed that the candidate achieved statistically significant improvements in clinically meaningful endpoints with a comparable safety profile to the current standard of care.
Based on the encouraging data from the study, the company is planning to file a new drug application to the FDA in the first half of 2020. It anticipates to commercially launch the candidate in early 2021.
Shares of Aurinia surged almost 120% in after-hours trading on Dec 4, following the data readout. The company’s shares have gained 23% so far this year compared with the industry’s increase of 10.6%.
The AURORA study evaluated immunosuppressant candidate, voclosporin, for increase in speed of and overall renal response rates in patients with LN when added to background therapy of mycophenolate mofetil, another immunosuppressant, and low-dose corticosteroids. Data showed that patients receiving voclosporin achieved 40.8% renal response rate compared to 22.5% for the standard of care following a treatment period of 52 weeks. The candidate also achieved improvement of statistical significance in all pre-specified hierarchical secondary endpoints. The candidate was also well tolerated in patients.
The company believes the data from the pivotal study demonstrates that voclosporin can be a potential game changer for LN patients. It also believes that the candidate is the first novel treatment that has demonstrated therapeutic efficacy and no excess adverse events compared to standard of care.
Meanwhile, the company is evaluating the candidate in AURORA 2 extension study in patients who have completed the AURORA study for a duration of 104 weeks to assess the long-term benefit/risk of voclosporin in LN patients. The company mentioned in its press release that data from the study should be valuable in a post-marketing setting and for future interactions with various regulatory authorities.
Apart from the LN indication, Aurinia is also developing voclosporin across multiple inflammatory and autoimmune conditions.
We note that there are several big pharma companies that are also developing treatments for lupus. Biogen’s (BIIB - Free Report) lupus candidate, BIIB059, met the primary endpoint in a phase II study earlier this month. A phase II study is evaluating Roche’s (RHHBY - Free Report) Gazyva as a treatment for LN patients. In August, AstraZeneca (AZN - Free Report) announced that anifrolumab met the primary endpoint of the phase III study evaluating it in lupus patients. We expect voclosporin to face competition from these drugs, upon their potential approval.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Aurinia's Lupus Candidate Succeeds in Pivotal Study, Stock Up
Aurinia Pharmaceuticals Inc. (AUPH - Free Report) announced that its pipeline candidate, voclosporin, met the primary endpoint in a pivotal phase III AURORA study evaluating it in patients with lupus nephritis ("LN"), an inflammation of the kidney caused by systemic lupus erythematosus. Data showed that the candidate achieved statistically significant improvements in clinically meaningful endpoints with a comparable safety profile to the current standard of care.
Based on the encouraging data from the study, the company is planning to file a new drug application to the FDA in the first half of 2020. It anticipates to commercially launch the candidate in early 2021.
Shares of Aurinia surged almost 120% in after-hours trading on Dec 4, following the data readout. The company’s shares have gained 23% so far this year compared with the industry’s increase of 10.6%.
The AURORA study evaluated immunosuppressant candidate, voclosporin, for increase in speed of and overall renal response rates in patients with LN when added to background therapy of mycophenolate mofetil, another immunosuppressant, and low-dose corticosteroids. Data showed that patients receiving voclosporin achieved 40.8% renal response rate compared to 22.5% for the standard of care following a treatment period of 52 weeks. The candidate also achieved improvement of statistical significance in all pre-specified hierarchical secondary endpoints. The candidate was also well tolerated in patients.
The company believes the data from the pivotal study demonstrates that voclosporin can be a potential game changer for LN patients. It also believes that the candidate is the first novel treatment that has demonstrated therapeutic efficacy and no excess adverse events compared to standard of care.
Meanwhile, the company is evaluating the candidate in AURORA 2 extension study in patients who have completed the AURORA study for a duration of 104 weeks to assess the long-term benefit/risk of voclosporin in LN patients. The company mentioned in its press release that data from the study should be valuable in a post-marketing setting and for future interactions with various regulatory authorities.
Apart from the LN indication, Aurinia is also developing voclosporin across multiple inflammatory and autoimmune conditions.
We note that there are several big pharma companies that are also developing treatments for lupus. Biogen’s (BIIB - Free Report) lupus candidate, BIIB059, met the primary endpoint in a phase II study earlier this month. A phase II study is evaluating Roche’s (RHHBY - Free Report) Gazyva as a treatment for LN patients. In August, AstraZeneca (AZN - Free Report) announced that anifrolumab met the primary endpoint of the phase III study evaluating it in lupus patients. We expect voclosporin to face competition from these drugs, upon their potential approval.
Aurinia Pharmaceuticals Inc Price
Aurinia Pharmaceuticals Inc price | Aurinia Pharmaceuticals Inc Quote
Zacks Rank
Aurinia currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>